Home / Publications / CMS advises Gilead Sciences on its agreement with...

CMS advises Gilead Sciences on its agreement with Pharmstandard JSC on the production of innovative treatment for hepatitis C and HIV


CMS Russia has advised Gilead Sciences on its localisation agreement with Pharmstandard JSC under which Pharmstandard’s production facilities will be used to manufacture Gilead’s medicines for treating chronic hepatitis С and HIV. This partnership will provide broad access to Gilead’s proprietary innovative methods for treating these diseases to many people in Russia.

Gilead Sciences, Inc. is a research biopharmaceutical company that has been a leading innovator in the area of HIV control for over 30 years. Gilead operates in more than 35 countries around the world.
Pharmstandard is a leading Russian pharmaceutical company. The company's production facilities include five factories located throughout Russia.

The CMS team was led by Counsel Vsevolod Tyupa, an expert in lifesciences. The leading international legal directory Chambers & Partners describes Vsevolod as a well-regarded lawyer advising both domestic and international clients on the localisation of healthcare businesses as well as on distribution, clinical trials and regulatory compliance.